CD8A and cancer: NKG2D is a type 2 transmembrane protein expressed in NK cells and CD8+ T cells, which is concurrently required for activation of the TCR for recognition of the targeted cancer cells.[18] SB‐3CT restored the NKG2D expression levels in MMP‐9‐treated TILs (Figure 6A,B).